Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 8/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.50 |
| ▸ | PTGES | O14684 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3561234 | 0.96 | ALOX5 (0.54) | ALOX5TRPM8PTGER1PTGESKEAP1 | |
| SCHEMBL3557886 | 0.92 | TRPM8 (0.48) | ALOX5TRPM8PTGER1PTGESL3MBTL1 | |
| SCHEMBL3552544 | 0.91 | ALOX5 (0.53) | ALOX5TRPM8PTGESKEAP1NFE2L2 | |
| SCHEMBL3557378 | 0.90 | ALOX5 (0.58) | ALOX5PTGESKEAP1NFE2L2ESR1 | |
| SCHEMBL3564284 | 0.90 | ALOX5 (0.58) | ALOX5TRPM8PTGESKEAP1NFE2L2 | |
| SCHEMBL3560865 | 0.90 | ALOX5 (0.57) | ALOX5PTGESKEAP1NFE2L2ESR1 | |
| SCHEMBL3559141 | 0.90 | MEN1 (0.48) | ALOX5TRPM8PTGER1PTGESL3MBTL1 | |
| SCHEMBL3552553 | 0.90 | ALOX5 (0.52) | ALOX5TRPM8PTGER1PTGESKEAP1 | |
| SCHEMBL3554627 | 0.89 | ALOX5 (0.57) | ALOX5TRPM8PTGESKEAP1NFE2L2 | |
| SCHEMBL3561595 | 0.88 | ALOX5 (0.56) | ALOX5TRPM8PTGESKEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | ALOX5 101/4885TRPM8 3817/4885PTGER1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.